BD Micro-Delivery System Licensed by Sanofi Pasteur; Technology has Potential to Improve Efficiency of Influenza Vaccine
FRANKLIN LAKES, N.J. -- BD (Becton, Dickinson and Company) has entered into an agreement with sanofi pasteur, the vaccines business of the sanofi-aventis Group, to license the BD Micro-Delivery System for use in the administration of sanofi pasteur's human vaccine products.
Most vaccines are delivered via intramuscular injection. This BD patented technology provides a new method of delivering vaccine into the upper layer of the skin. The results of early-phase clinical research have shown that this method of delivery has the potential to improve the immunogenicity and efficiency of the delivered vaccine.
"We are very pleased to enter into this collaboration with sanofi pasteur," said Gary Cohen, president of BD Medical. "We believe that our BD Micro-Delivery System has the potential to help address some of the important health challenges facing the world today, and embodies BD's company purpose of helping all people live healthy lives."
The BD Micro-Delivery System is designed to be pre-filled with vaccine and to easily and reliably deliver the vaccine to the skin. The system features a tiny "microneedle." Clinical testing indicates that the "microneedle" is barely perceptible when it enters the skin.
"In practical terms, the BD Micro-Delivery System has the potential to increase a patient's acceptance of vaccine as well and enable vaccination of more people with less vaccine," said Alexandre Conroy, president of BD Medical Pharmaceutical Systems.
Under the terms of the agreement, BD will provide sanofi pasteur with a license to the BD Micro-Delivery System in the field of human vaccines. The parties will continue to work together to demonstrate its applicability to delivering a wide variety of vaccines, including the influenza vaccine that is now being tested in human clinical trials conducted in conjunction with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID).
Per the agreement, BD will be compensated for use of the BD Micro-Delivery System provided to sanofi pasteur, which will develop, manufacture and commercialize the vaccine-filled BD Micro-Delivery Systems.
Source: sanofi pasteur, BD
Â
Â
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
